Aug 2026· Journal of Gastroenterology and Hepatology· Vol 41, pp. 3188 - 3198· 0 citations· 36 references
Medicine
TL;DR
The association between hepatic steatosis and poorer LDL-C response to statins, if any, is not clinically significant and patients with hepatic steatosis are recommended to receive a standard statin dose according to clinical indications.
Abstract
Metabolic dysfunction–associated steatotic liver disease (MASLD) is strongly associated with dyslipidemia, which is a major risk factor for cardiovascular diseases and the leading cause of mortality in MASLD. This study aimed to compare the low‐density lipoprotein cholesterol (LDL‐C) response to statins in patients with and without hepatic steatosis.
BACKGROUND
Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent among individuals with severe obesity. The triglyceride-to-high-density lipoprotein cholesterol ratio (TG/HDL-C) is an accessible surrogate marker of insulin resistance, but its association with hepatic steatosis and fibrosi...
Carolina de Oliveira Bernardes, Esdras Marques Lins, Fernanda Appolônio Rocha et al.· Obesity Surgery· 0 citations
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes (T2DM) have been associated with dyslipidemia. This study aimed to investigate the association between lipid values and markers of hepatic steatosis and fibrosis in patients with T2DM. Methods: This is a post hoc analysis o...
Laura A M Konings, Weiwei Xu, Vivian D. de Jong et al.· Diabetology· 0 citations
In a primary care population, statin prescriptions were associated with a lower risk of fibrosis progression and SLD in patients with chronic liver disease.
Nicholas P. Smith, A. Schreiner, Jing-Wen Zhang et al.· Clinics And Research in Hepa...· 0 citations
BACKGROUND AND AIMS
Low-density lipoprotein cholesterol (LDL-C) is a causal risk factor for atherosclerotic cardiovascular disease (ASCVD). ESC/EAS guidelines recommend reducing LDL-C < 1.4 mmol/L and > 50% from baseline in patients with myocardial infarction. "Jena auf Ziel" (JaZ) is a prospective cohort study in whic...
U. Makhmudova, D. Lütjohann, F. Haertel et al.· Herz· 0 citations
In a contemporary AMI cohort, combined LLT remained low at presentation and discharge despite suboptimal LDL-C, underscoring actionable gaps in ASCVD management.
Mohammed Essa, Qifan Wu, Yuan Lu et al.· JACC: Advances· 1 citation
